Anti-inflammatory drug design by molecular hybridization approach
dc.contributor | Universidade Estadual Paulista (Unesp) | |
dc.date.accessioned | 2016-01-28T16:56:31Z | |
dc.date.available | 2016-01-28T16:56:31Z | |
dc.date.created | 2016-01-28T16:56:31Z | |
dc.date.issued | 2011 | |
dc.identifier | Pharmaceuticals, v. 4, p. 1450-1474, 2011. | |
dc.identifier | 1424-8247 | |
dc.identifier | http://hdl.handle.net/11449/133761 | |
dc.identifier | 10.3390/ph4111450 | |
dc.identifier | ISSN1424-8247-2011-04-1450-1474.pdf | |
dc.identifier | 4083068210623663 | |
dc.identifier | 3204277043366119 | |
dc.identifier | 5435899068903487 | |
dc.identifier | 9734333607975413 | |
dc.identifier | 5737933639516944 | |
dc.identifier | 0000-0003-4141-0455 | |
dc.description.abstract | The design of new drugs with better physiochemical properties, adequateabsorption, distribution, metabolism, and excretion, effective pharmacologic potency andlacking toxicity remains is a challenge. Inflammation is the initial trigger of severaldifferent diseases, such as Alzheimer s disease, asthma, atherosclerosis, colitis, rheumatoidarthritis, depression, cancer; and disorders such as obesity and sexual dysfunction.Although inflammation is not the direct cause of these disorders, inflammatory processesoften increase related pain and suffering. New anti-inflammatory drugs developed usingmolecular hybridization techniques to obtain multiple-ligand drugs can act at one or multipletargets, allowing for synergic action and minimizing toxicity. This work is a review of newanti-inflammatory drugs developed using the molecular modification approach. | |
dc.language | eng | |
dc.relation | Pharmaceuticals | |
dc.relation | 1,293 | |
dc.rights | Acesso aberto | |
dc.source | Currículo Lattes | |
dc.subject | Anti-inflammatory | |
dc.subject | Hybridization | |
dc.subject | Multiple-ligands | |
dc.subject | Mutual prodrug | |
dc.title | Anti-inflammatory drug design by molecular hybridization approach | |
dc.type | Artículos de revistas |